Table 2 Comparison of demographic, laboratory, and radiological characteristics in the group 1 based on liver stiffness, with comparison to the control group treated with DAAs

Age

42.9 ± 3.34

44.6 ± 4.3

40.3 ± 3.56

0.001

M/F

112/33

81/24

84/46

0.087

ALT IU/L

57.9± 5.9

66.4± 10.7

87.6± 15.9

0.001

AST IU/L

54.7 ± 9.2

72.2 ± 5.4

55 ± 8.3

0.001

Albumin (gm/dl)

3.97 ± 0.22

3.2 ± 0.33

4.32 ± 0.36

0.001

γ- globulin (gm/dl)

3.24±0.14

4.15±0.37

3.41±0.29

0.001

Total bilirubin (mg/dl)

1.11 ± 0.13

1.49± 0.22

1.03 ± 0.19

0.001

Platelet count( cell/ul)

101.8 ± 19

83± 13.8

164 ± 14

0.001

PDW/MPV

2.29±0.48

3.58±0.33

1.58±0.27

0.001

PC%

63.5 ± 4.3

52.5 ± 4.1

76 ± 6.2

0.001

CTP

6

6

5

-

Sodium

140±3.3

136.4±4.5

141±3.8

0.001

Ammonia (ug/dl)

65.1±14.7

94.7±13

43±11.6

0.001

Creatinine (mg/dl)

1.11±0.19

1.24±0.2

0.96±0.35

0.001

MELD

11.6±1.7

15.5±1.6

7.7±0.94

0.001

LSM by fibroscan (kPa)

18.3±1.6

27.5±2.9

8.2±0.86

0.001

- liver volume (ml)

623.5 ± 64.7

502 ± 41.9

1268 ± 81.2

0.001

Complications (n=123)

31 (25.2%)

89 (72.4%)

3(2.4%)

0.0001

-Hepatic decompensation (34)

12

22

-

0.0001

-upper GIT bleeding (1)

-

1

-

0.77

-cardiomyopathy (6)

-

6

-

0.0403

-virological relapse (64)

15

46

3

0.00001

-HCC (18)

4

14

-

0.0001

SVR (316)

118/145 (81.4%)

71/105 (67.6%)

127/130 (97.7%)

0.0001